KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Debt to Equity (2019 - 2025)

Historic Debt to Equity for Rigel Pharmaceuticals (RIGL) over the last 7 years, with Q3 2025 value amounting to $0.51.

  • Rigel Pharmaceuticals' Debt to Equity rose 11243.8% to $0.51 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.51, marking a year-over-year increase of 11243.8%. This contributed to the annual value of $18.15 for FY2024, which is 97230.8% up from last year.
  • As of Q3 2025, Rigel Pharmaceuticals' Debt to Equity stood at $0.51, which was up 11243.8% from $0.73 recorded in Q2 2025.
  • Rigel Pharmaceuticals' Debt to Equity's 5-year high stood at $18.15 during Q4 2024, with a 5-year trough of -$8.11 in Q2 2022.
  • Moreover, its 5-year median value for Debt to Equity was -$1.87 (2023), whereas its average is -$0.05.
  • Within the past 5 years, the most significant YoY rise in Rigel Pharmaceuticals' Debt to Equity was 163237.13% (2022), while the steepest drop was 288268.5% (2022).
  • Rigel Pharmaceuticals' Debt to Equity (Quarter) stood at $0.66 in 2021, then crashed by 541.89% to -$2.9 in 2022, then grew by 28.18% to -$2.08 in 2023, then skyrocketed by 972.31% to $18.15 in 2024, then plummeted by 97.2% to $0.51 in 2025.
  • Its last three reported values are $0.51 in Q3 2025, $0.73 for Q2 2025, and $3.22 during Q1 2025.